company background image
ATRA

Atara Biotherapeutics NasdaqGS:ATRA Stock Report

Last Price

US$3.85

Market Cap

US$356.7m

7D

13.6%

1Y

-77.9%

Updated

03 Oct, 2022

Data

Company Financials +
ATRA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ATRA Stock Overview

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States.

Atara Biotherapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Atara Biotherapeutics
Historical stock prices
Current Share PriceUS$3.85
52 Week HighUS$20.04
52 Week LowUS$2.83
Beta0.95
1 Month Change-10.26%
3 Month Change-55.90%
1 Year Change-77.94%
3 Year Change-72.58%
5 Year Change-75.00%
Change since IPO-67.92%

Recent News & Updates

Sep 28

Atara Bio to get additional $30M milestone payment under collaboration with Pierre Fabre

Atara Biotherapeutics (NASDAQ:ATRA) on Wednesday said it had amended the terms of its existing collaboration agreement with French pharmaceutical company Pierre Fabre for the commercialization of its tabelecleucel therapy for the treatment of Epstein-Barr virus-positive cancers. ATRA said it would now get an additional $30M milestone payment upon European Commission approval and subsequent filing of the marketing approval transfer to Pierre Fabre. In exchange, Pierre Fabre would get reduced tabelecleucel royalties and supply price-mark up. Tiered royalties on sales remain at a significant double-digit rate following the amendment, ATRA said in a statement. The company added that the anticipated European Commission approval for tabelecleucel was on track for Q4. Atara Biotherapeutics (ATRA) stock earlier closed more than 15% higher.

Aug 17

Atara: 2 Possible Regulatory Approvals For Tab-Cel, Plus CAR T Pipeline

Atara has two possible regulatory approvals for tab-cel for PTLD; European approval expected Q4 of 2022 and BLA filing for U.S. territory to be updated in next quarter earnings call. Two data readouts of ATA188 for treatment of patients with progressive multiple sclerosis; Phase 1 MRI Data/OLE data Q4 2022 and phase 2 EMBOLD study data expected October 2023. IND filing for the use of a CAR-T known as ATA3219 for the treatment of patients with B-cell malignancies expected Q4 of 2022. Atara had $331.3 million in cash as of June 30, 2022; Enough to fund its operations into Q1 of 2024. Atara Biotherapeutics, Inc. (ATRA) is a great speculative biotech play to look into. That's because it is one step closer to getting its T-cell immunotherapy, known as tabelecleucel (tab-cel), approved for the treatment of patients with Post-Transplant Lymphoproliferative Disease ((PTLD)). A Marketing Authorization Application ((MAA)) has been submitted and European Commission ((EC)) approval of tab-cel for this specific indication is expected in Q4 of 2022. In terms of the FDA, it has already spoken with the agency and it believes it may be possible to file a Biologics Licensing Application ((BLA)) to the FDA for tab-cel for PTLD without the need for a new trial. An update on what the biotech plans to do is going to be provided upon the next quarterly call earnings for it. Besides these two catalysts, there is another drug which may yield such potential. This involves the use of AT188 for the treatment of patients with progressive multiple sclerosis ((MS)). There will be a catalyst approaching in which Atara will provide new phase 1 MRI data and open label extension ((OLE)) data at an upcoming medical presentation in Q4 of 2022. This provides another shot on goal for investors/traders to look forward to. Lastly, final data from the ongoing phase 2 EMBOLD study, using ATA188 for the treatment of patients with progressive MS is expected at a medical forum presentation in October of 2023. With an expanding pipeline with several drug candidates, plus several catalysts expected within the coming year, these are the reasons why I believe it is a great speculative biotech play to look into. Tabelecleucel For Post-Transplant Lymphoproliferative Disease The main program to go over for Atara would be the use of tabelecleucel ((tab-cel)) for post-transplant lymphoproliferative disease. Specifically, it is being used for solid organ or allogenic hematopoietic cell transplant patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+PTLD) The phase 3 ALLELE study, which I will be going over below, is using tab-cel to treat these patients who have already tried and failed with Rituximab alone or Rituximab + chemotherapy. Before diving into the phase 3 study itself, it's important to understand what EBV and PTLD mean. Epstein Barr Virus ((EBV)) is a member of the herpes family virus. It can also be called Herpesvirus 4. The primary way that this is spread is through bodily fluids between people, more profoundly with saliva. What makes it so dangerous, though, is that it can cause infectious mononucleosis or other diseases as well. There are several symptoms which are associated with this disease and they are as follows: Inflamed throat Fever Rash Fatigue Swollen lymph nodes Enlarged Spleen Several other symptoms However, even if these are the symptoms, there are a few other things to keep in mind when it comes to this particular virus. For patients who do end up getting EBV, they may not experience severe symptoms. Even if they do get infected with it, symptoms may only last 2 to 4 weeks. The main symptom that these patients may experience might be fatigue but that can last for several more weeks or even possibly months. Another item to be aware of is that the virus may become inactive, meaning it does not cause any issues with the body. The downside is that at any moment it's possible that it can reactivate and then become a major problem afterwards. Now that you know what EBV is, it is time to go over what Post-Transplant Lymphoproliferative disease ((PTLD)) itself means. PTLD is a group of disorders that can occur after a transplant is done. When a patient receives such a transplant it causes the immune system, more specifically, lymphocytes (white blood cells) to multiply in a highly rapid fashion. If the lymphocyte grows to a large type then it is not really much of an issue. However, if it becomes abnormal (lymph node cancer) then it is lymphoma. As you can see, this becomes a major problem for the patient. Wait a second, so how exactly does EBV + PTLD occur? There are two scenarios where this happens. The first scenario is when a patient who receives a transplant from an infected donor. That's because when an organ or stem cell is donated, the patient receives all other cells even including B-cells. That is, Epstein-Barr infected B-cells come directly from the donor. The second scenario occurs when a patient receives a transplant and then gets infected with Epstein Barr Virus ((EBV)) for the first time. That is, the disease doesn't come from the donor, but occurs as a result of the transplant itself. Either way, these patients suffer from this disease. The only main drug used to treat EBV + PTLD is Rituximab (RITUXAN). If Atara Biotherapeutics can gain European approval or U.S. FDA approval of tab-cel for this specific indication, it would be huge. As I noted above, there is an ongoing open-label phase 3 registration study known as ALLELE. Again, this study is investigating the use of tab-cel for the treatment of EBV + PTLD following solid organ transplant ((SOT)) or hematopoietic cell transplant ((HCT)). The primary endpoint being assessed for this study is objective response rate ((ORR)) over a 2-year period. The thing is that this phase 3 study did well in still establishing that tab-cel was highly prominent in helping patients. I note this because 90% of patients who achieved a response to this treatment from Atara Biotherapeutics survived after one year. Another item to note is that in a prior phase 2 study 86% of patients who achieved a complete response ((CR)) or partial response ((PR)) survived after two years. As of a cut off date of May 2021 with about 38 evaluable patients, data was reported. The split among the patients for this particular study is as follows: 24 EBV + PTLD patients following solid organ transplant after failure of rituximab + chemotherapy 14 EBV + PTLD patients following Hematopoietic cell transplant ((HCT)) after failure of rituximab monotherapy All patients were treated with tab-cel and then had opportunity to be followed for 6 months after having obtained a response. One major thing to note on why I believe this data is sufficient is because these are patients who took a median (average) of 1 (range 1 to 5) prior systemic treatments including rituximab monotherapy, chemotherapy or immunotherapy. It was noted that a 50% objective response rate (ORR) was observed for EBV + PTLD patients following either a solid organ transplant or for those with a hematopoietic cell transplant ((HCT)). As far as objective response rate ((ORR)) goes this study was successful in meeting the primary endpoint. However, what I would also like to point out is that there was a major difference for those who responded to tab-cel and then for those who didn't respond. For instance, for those who responded to tab-cel, the one-year survival rate was 89.2%. On the other hand, for those who didn't respond to tab-cel, one-year survival rate was 32.4%. Besides meeting the primary endpoint, it is nice to see that the overall survival rate was greatly improved for those who actually did take tab-cel. One other item to note is that about 11 out of 19 responders had a duration of response ((DOR)) lasting more than 6 months as well. Based on the data, Atara Biotherapeutics has already filed a Marketing Authorization Application ((MAA)) to the European Medicines Agency ((EMA)) for potential regulatory approval for tab-cel for solid organ or allogenic hematopoietic cell transplant patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease ((EBV+PTLD)). The EMA validated the regulatory application of tab-cel for this specific indication back on November 30, 2021. There are a few reasons why this is great news for this company. The first reason is because it is the first ever off-the-shelf allogeneic T-cell Therapy to be reviewed by any regulatory agency across the globe for starters. The second reason is because it is the most advanced cell therapy from the biotech in the pipeline (most advanced program). The final reason is because it would allow it to have its first regulatory approved T-cell therapy on the market. As such, there is a major catalyst opportunity which investors can look forward to as it relates to this specific program. It is expected that Atara could possibly receive EMA regulatory approval for tab-cel for EBV + PTLD by Q4 of 2022. A decision for possible regulatory approval for the European territories is still expected by the Q4 of 2022 timeline. As far as the FDA goes that is 50/50 on to whether or not a regulatory filing can happen. I state that because for the time being Atara is in active discussions with the FDA on the potential to file tab-cel for EBV + PTLD for the U.S. market. The good news it seems is that based on discussion Atara had with the FDA, another study will likely not be required. An update on the BLA filing for the U.S. market will be updated at the company's next quarterly earnings call. There is another positive for Atara as it relates to tab-cel and that is the ability to expand it towards other EBV associated disorders. This is possible because there is a multi-cohort phase 2 study using tab-cel in 6 additional patient populations for EBV+ immunodeficiency associated lymphoproliferative diseases (IA-LPDs) and other EBV-driven diseases. This study is continuing to enroll patients in both the United States and Europe. There is a catalyst opportunity which relates to this mid-stage study. It is expected that the first set of results from the multi-cohort phase 2 study, using tab-cel in 6 additional EBV+ patient populations, will be released for a presentation in 2023. This is going to be important, because proof of concept for EBV + PTLD has been already established. It could possibly allow this biotech to expand the label of its treatment towards other EBV+ diseases. Of course, that is if it ultimately receives regulatory approval for tab-cel for this indication in Europe or in the United States. Financials According to the 10-Q SEC Filing, Atara Biotherapeutics had cash, cash equivalents and short-term investments of $331.3 million as of June 30, 2022. The reason for the large increase in its cash position is because it enacted the sale of the ATOM facility during Q2 of 2022, in which it generated net proceeds of $94.8 million from it. Based on its current cash on hand, it believes it has enough to fund its operations into Q1 of 2024. I believe that this should be sufficient cash for the time being. However, it has a 2021 ATM Facility sales agreement with Coen, which was developed back in November of 2021. This agreement allowed for the aggregate offering price of up to $100 million through Cowen, which was the sales agent.

Shareholder Returns

ATRAUS BiotechsUS Market
7D13.6%0.4%-2.5%
1Y-77.9%-25.6%-23.2%

Return vs Industry: ATRA underperformed the US Biotechs industry which returned -25.6% over the past year.

Return vs Market: ATRA underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is ATRA's price volatile compared to industry and market?
ATRA volatility
ATRA Average Weekly Movement23.4%
Biotechs Industry Average Movement11.1%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: ATRA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.

Volatility Over Time: ATRA's weekly volatility has increased from 15% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012570Pascal Touchonhttps://www.atarabio.com

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis.

Atara Biotherapeutics, Inc. Fundamentals Summary

How do Atara Biotherapeutics's earnings and revenue compare to its market cap?
ATRA fundamental statistics
Market CapUS$356.69m
Earnings (TTM)-US$247.65m
Revenue (TTM)US$71.81m

5.1x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ATRA income statement (TTM)
RevenueUS$71.81m
Cost of RevenueUS$257.27m
Gross Profit-US$185.45m
Other ExpensesUS$62.20m
Earnings-US$247.65m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.62
Gross Margin-258.25%
Net Profit Margin-344.87%
Debt/Equity Ratio0%

How did ATRA perform over the long term?

See historical performance and comparison